Company news

Syndax Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

November 2, 2026

Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer

November 2, 2026

Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases

October 30, 2026

Syndax Announces Participation in November Investor Conferences

October 30, 2026

Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026

October 26, 2026

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

October 15, 2026

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

October 12, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

October 2, 2026

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

August 4, 2026

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

July 28, 2026

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

July 14, 2026

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

June 11, 2026

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

June 11, 2026

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

June 3, 2026

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

June 2, 2026

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

June 1, 2026

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

May 21, 2026

Syndax Announces Participation in Upcoming Investor Conferences

May 20, 2026

Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition

May 12, 2026

Syndax Reports First Quarter 2026 Financial Results and Provides Business Update

April 29, 2026

Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

April 24, 2026

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 25, 2026

Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

February 19, 2026

Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

February 4, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 4, 2026

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

January 11, 2026

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

January 6, 2026

Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

December 11, 2025

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

December 7, 2025

Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

November 30, 2025

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

November 2, 2025

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

November 2, 2025

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

November 2, 2025

Syndax Announces Participation in November Investor Conferences

October 29, 2025

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025

October 26, 2025

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

October 23, 2025

CREATE Medicines Strengthens Executive Team with Appointment of Veteran Biopharma Leader Allan L. Shaw as CFO and CBO

October 8, 2025

Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

September 18, 2025

Syndax Announces Participation in September Investor Conferences

August 25, 2025

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

August 3, 2025

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

July 27, 2025

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

June 23, 2025

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

June 11, 2025

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

June 11, 2025

Syndax Announces Participation in June Investor Conferences

May 28, 2025

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)

May 13, 2025

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

May 11, 2025

Syndax Announces Participation in May Investor Conferences

May 7, 2025

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

May 6, 2025

Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 43 decks. Every deck is listed under its year.